Form 4 for DBD DIEBOLD NIXDORF, Inc
Accepted 2024-01-23 00:00:00 ET · period of report 2024-01-19 · accession 0000950170-24-006593 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-23 | 2024-01-19 | DBD | Barna James | EVP, CFO | A - Grant | $0.00 | +8,139 | 8,139 | New | $0 |
| D | 2024-01-23 | 2024-01-19 | DBD | Barna James | EVP, CFO | A - Grant | $0.00 | +40.7K | 40.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-19 | A | A | 8,139 | $0.00 | 8,139 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-01-19 | A | A | 40,696 | $0.00 | 40,696 | D | $30.90 · — to 2034-01-19 | 40,696 Common Stock | (F1) Granted under the Diebold Nixdorf, Incorporated 2023 Equity and Incentive Plan, as amended; option generally vests on the fourth anniversary of January 19, 2024, and is generally exercisable in 40%, 30% and 30% tranches upon the Issuer's common stock, par value $0.01 per share, achieving 20-day trading average price hurdles of $65.00, $85.00 and $95.00, respectively, by January 19, 2028. |